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Introduction: This case report presents for the first time an acute systemic allergic reaction to corticosteroids in a
patient with ocular toxoplasmosis after treatment with intravenous cortisone, and discusses alternative treatments.
Case presentation: We present the case of a 57-year-old Caucasian woman with an anaphylactic reaction after
intravenous injection of prednisolone-21-hydrogensuccinate (Solu-Decortin® H) given for the treatment of
toxoplasmosis-associated chorioretinitis. Immediately after the injection, she developed an acute erythema of the
legs and abdomen, angioedema, hypotension (blood pressure 80/40mmHg), tachycardia (heart rate 140/minute),
hyperthermia (38.8°C), and respiratory distress. Allergological examinations showed a positive skin-prick test to
prednisolone and methylprednisolone. In addition, an oral exposure test with dexamethasone (Fortecortin®) and
betamethasone (Celestamine®) was conducted to find alternative corticosteroids for future treatments. After oral
application, no local or systemic reactions were observed for these two substances.
Conclusions: This case report demonstrates that systemic allergic reactions are possible in patients with uveitis or
other inflammatory ophthalmological conditions treated with intravenous corticosteroids. Intravenous
administration of cortisone, for example, in the treatment of ocular toxoplasmosis, should always be conducted
with caution because of a possible allergic reaction. For patients who react to a particular steroid, it is necessary to
undergo allergological testing to confirm that the compound in question is indeed allergenic, and to identify other
corticosteroids that are safe for future anti-inflammatory treatments.
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Glucocorticoids are among the most effective and lon-
gest known pharmaceuticals for the suppression of
immunological reactions. Since their initial therapeutic
use in medicine in 1948 [1], they have been used for their
anti-inflammatory effect in a variety of indications. There
are also a lot of indications in ophthalmology, for example,
treatment of uveitis or ocular toxoplasmosis (OT). How-
ever, since their first use, many intolerance reactions have
been described. These were mainly reported for local [2],
intramuscular [3], oral [4], and inhalation [5] applications.
Only a few cases report an anaphylactic reaction after
intravenous administration of cortisone [6,7]. Therefore,* Correspondence: Achim.Fiess@hsk-wiesbaden.de
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reproduction in any medium, provided the orwe report for the first time the case of a systemic allergic
reaction by a patient with OT treated with a single dose of
intravenous prednisolone-21-hydrogensuccinate (Solu-
Decortin® H) to reduce the ocular inflammatory response
of OT.
Case presentation
A 57-year-old Caucasian woman reported a decrease in
visual acuity for 2 weeks. Her best-corrected visual acuity
for her right eye was 20/20 and for her left eye 20/100. A
slit-lamp examination and intraocular pressure were unre-
markable in both eyes. Fundus examination of her left eye
revealed temporal intraretinal infiltrates and vitreous
opacities (Figure 1). Her right eye was unremarkable.
Fluorescein angiography showed hyperfluorescence of
her optic disc, leakage along the vessels, and chorioretinal
hyperfluorescent infiltrates (Figure 2). The diagnosis of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Fundus examination of the left eye revealed vitreous opacities and chorioretinal infiltrates.
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sions and a positive serological testing for Toxoplasma
gondii (immunoglobulin G concentration = 537IU/mL).
She was treated with clindamycin (Clindamycin® H)
4 × 300mg daily over 3 days without any significant
improvement of visual acuity. On the fourth day of
hospitalization, she received 100mg prednisolone-21-
hydrogensuccinate (Solu-Decortin® H) intravenously in
addition to her treatment with clindamycin (Clindamycin®
H). Within 2 minutes she developed an acute erythema,
particularly of her legs and abdomen (Figure 3), angio-
edema, hypotension (blood pressure 80/40mmHg), tachy-
cardia (heart rate 140/minute), hyperthermia (38.8°C), and
respiratory distress. Subsequently, she was transferred to
the Intensive Care Unit to be monitored and treated with
clemastine fumarate (Tavegil®), ranitidin (Ranitic®), and
intravenous fluids. After 1 hour she recovered and after
12 hours she was transferred back to the ophthalmo-
logical ward. Her erythema and angioedema persisted for
32 hours. She had no history of previous steroid use. Sub-
sequent allergy testing was conducted after 3 months in
the Department of Dermatology in our hospital. The test-
ing showed a positive skin-prick test for prednisolone
and methylprednisolone in the form of a 5mm wheal, and
negative results for dexamethasone and hydrocortisone
(Table 1), which confirmed her suspected allergy to pred-
nisolone. Because of her allergic reaction to class A (pred-
nisone-type) corticosteroids and possible complications
due to cross-reactions to class D2 (prednicarbate-type)Figure 2 Fluorescein angiography of the left eye revealed vitreous op
vessels, and chorioretinal infiltrates.corticosteroids, we avoided any further treatment with
systemic or intravitreal corticosteroids.
In addition, an oral exposure test with a step-by-step ele-
vation of doses up to 2.0mg of dexamethasone (Fortecortin®)
and 1.5mg betamethasone (Celestamine®) was conducted
to find alternative corticosteroids for future treatments.
For both substances, no local or systemic side effects were
observed.
After 1 month of treatment with clindamycin (Clinda-
mycin® H) monotherapy without any increase in visual
acuity, the patient underwent a vitrectomy with balanced
salt solution filling because of heavy vitreous opacities,
and to obtain a sample of the vitreous body. The poly-
merase chain reaction (PCR) on the sample was positive
for Toxoplasma gondii.
The postoperative examination of her left eye revealed
chorioretinal scars and infiltrates (Figure 4). Her right
eye was still unremarkable. Fluorescein angiography of
her left eye also revealed hyperfluorescent intraretinal
infiltrates of the temporal hemisphere and a scar of the
inferotemporal retinal vein branch (Figure 5). Her visual
acuity recovered to right eye 20/20 and left eye 20/40.
Discussion
The first unquestionable anaphylactic reaction to intra-
venous corticosteroids was described in the year 1974
after treatment of a patient with methylprednisolone and
hydrocortisone during an acute asthma attack [6]. The
medical literature describes only approximately 40 casesacities, a hyperfluorescence of the optic disc, leakage along the
Figure 3 Erythema, particularly of the legs and abdomen, and angioedema after intravenous injection of prednisolone (photo was
taken after return from Intensive Care Unit).
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tisone [8,9]. Moreover, this is the first reported case of
an acute allergic reaction to intravenous prednisolone in
a patient with OT. Accordingly, this case demonstrates
that the use of intravenous cortisone requires caution
because of a possible allergic reaction, albeit very rare.
In the case of a severe systemic reaction to intravenous
corticosteroids, we advise allergological testing of theTable 1 Skin-prick test















0.9% Sodium chloride –
Positive (+) tests for prednisolone and methylprednisolone in the skin-prick
test. The other compounds tested produced negative (-) test results in the
skin-prick test and all compounds showed negative results in the
epicutaneous test.most frequently administered corticosteroids and of all
other components of the administered formulation. This
is, on the one hand, to find the compound responsible
for the allergic reaction and, on the other hand, to iden-
tify corticosteroids for future treatment.
A few publications report a dramatic clinical course
with subsequent death of the patient after intravenous ad-
ministration of corticosteroids. However, in these cases
the correlation between intravenous corticosteroids and
subsequent death was hypothesized only due to the
chronological connection [10,11]. Our patient showed the
typical signs of anaphylaxis as described in a few publica-
tions and recovered completely after 2 days [12]. However,
the hyperthermia of the patient after the cortisone admin-
istration is not a typical feature of anaphylaxis. Neverthe-
less, since there was no concurrent infection other than
OT, it was concluded that hyperthermia was part of the
anaphylactic reaction in this case, although it is not com-
monly so.
In the literature, there is epidemiological data about
the incidence of corticosteroid allergies. In a routine epi-
cutaneous test in 2073 patients there was a positive test
result in 61 patients (2.9%) [13]. In a study by Alexiou
et al. [12], in three of 300 patients an anaphylactic reaction
to prednisolone-21-hydrogensuccinate (Solu-Decortin® H)
occurred during a 3-day therapy with intravenous corti-
sone up to 1000mg per day. This would correspond to a
frequency of 1%. In contrast to this study, the number of
case reports in the medical literature is very low [8,9].
To confirm the suspected allergy to corticosteroids in
the present case, a skin-prick test and an epicutaneous
test were carried out. The skin-prick test was performed
Figure 4 Fundus examination of the left eye after vitrectomy revealed a clearer insight, and chorioretinal scars.
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lancet in an area where a drop of the possible allergenic
solution had been applied. Immediately after puncturing
the antigen solution was wiped off and following 5 to
15 minutes and 24 hours, the skin reaction was evalu-
ated. A positive reaction was noted if there was a wheal
at the puncture. There was a positive control (histamine
application) and a negative control (0.9% sodium chlor-
ide application). In the present case, the skin-prick test
was positive in the form of a 5mm wheal for prednisol-
one and methylprednisolone after 24 hours. Due to the
fact that the skin-prick test was positive for pure prepa-
rations of corticosteroids, there was no need to test for
other candidate substances. Solu-Decortin® H is sealed
in glass ampules under nitrogen, which can hardly be a
cause for an allergy. If there had been additional ingredi-
ents such as preservatives, these should have been tested
as well. It is important to conduct allergological testing
for every suspected substance because every compound
administered could indeed be allergenic. Given the posi-
tive prick-test an intracutaneous test was waived be-
cause of the danger of a possible anaphylactic reaction.
The epicutaneous test of our patient was negative for all
substances being tested. This could be because an epicuta-
neous test is a test for Type IV reactions. The epicuta-
neous test was performed to test if the patient had a
possible contact allergy for corticosteroids. However, the
anaphylactic reaction in our case was a Type I reaction,
which could be confirmed with the skin-prick test that
tests Type I reactions. Overall, immunological reactions toFigure 5 Left eye showing chorioretinal infiltrates and a temporal scasystemic corticosteroids are frequently of Type I according
to the classification by Gell and Coombs [14].
Detection of antibodies is often difficult because there
are no specific data for the technical analysis of serum
samples. Specific serum IgE antibodies to corticosteroids
were detected in only a few cases [15-17] and often anti-
bodies could not be found [12].
The clinical course of OT is usually self-limiting but
can recur after years. However, in some cases, OT can lead
to loss of vision, optic nerve or macular affection, and vit-
reous opacities [18]. Previous studies [19] have shown that
pars plana vitrectomy can be performed safely on patients
with OT who suffer from vitreoretinal complications. Our
findings in this case report are consistent with these re-
sults. In the case of our patient, after the vitrectomy, her
visual acuity recovered due to the removal of vitreous
opacities. Moreover, another benefit is the diagnostic cer-
tainty obtained by conducting PCR analysis on a sample
of vitreous body when a diagnosis remains inconclusive
solely based on clinical symptoms.
The most common therapy for OT is a triple therapy
consisting of pyrimethamine, sulfadiazine, and corticoste-
roids [20]. Steroids are successful in reducing the ocular in-
flammatory response. To reduce ocular inflammation, the
use of intravitreal triamcinolone or dexamethasone is an
alternative treatment for patients with OT. A study by
Soheilian et al. [21] compared intravitreal injection of clin-
damycin and dexamethasone with the standard treatment
for OT, consisting of systemic pyrimethamine, sulfadiazine,
and prednisolone. The authors showed that intravitrealr as detected by fluorescein angiography.
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lower systemic side-effects and greater convenience than
systemic OT medications. However, in the case of a proven
prednisolone allergy, intravitreal injection of an alternative
steroid, for example dexamethasone, would only be feasible
if an allergic reaction towards the intravitreal deposit of the
drug can definitely be excluded. Due to the possibility of
an allergic cross-reaction toward dexamethasone, which
would probably reside in the eye for weeks after intravitreal
deposition, we strictly avoided such a treatment.
Conclusions
In summary, this case report demonstrates that systemic
allergic reactions are possible in patients with uveitis or
other inflammatory ophthalmological conditions treated
with intravenous corticosteroids. Intravenous adminis-
tration of cortisone, for example in the treatment of OT,
should always be conducted with caution because of a
possible allergic reaction. For patients who react to a par-
ticular steroid, it is necessary to undergo allergological
testing to confirm that the compound in question is in-
deed allergenic, and to identify other corticosteroids that
are safe for future anti-inflammatory treatments.
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